GLPwatch
Effect of LY2189265 on Insulin Secretion in Response to Intravenous Glucose
NCT01300260 · Completed
Last updated 2026-05-28This clinical trial tested the effect of the medication LY2189265 on insulin secretion in response to glucose in adults with type 2 diabetes.
Status Completed The study has finished.
Phase Phase 1 Checks safety and dosing in a small group.
Type Interventional (clinical trial)
Design Randomized, triple-blind treatment study
Participants 32 people
Who can join Ages 18–65 · all sexes Healthy volunteers accepted.
Timeline Started 2011-02 · est. completion 2011-08
Where 1 site · Germany
What this study is testing ClinicalTrials.gov NCT01300260 ↗
Description as written by the study sponsor.
The purpose of this study is to measure the effect of LY2189265 to increase insulin levels in response to glucose intake.
Treatments tested
- LY2189265 also known as Dulaglutide Biologic
Administered subcutaneously
- Placebo Drug
Administered subcutaneously
- Insulin also known as Lispro Drug
Administered intravenously
- Glucose also known as Dextrose Drug
Administered intravenously
- Glucagon also known as Glucagon hydrochloride Drug
Administered intravenously
| Main thing measured | Maximum Insulin Concentration (Cmax) - First Phase Response |
|---|---|
| Sponsor | Eli Lilly and Company |
| Conditions studied | Diabetes Mellitus, Type 2 |
| GLP-1 drugs | — |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01300260 ↗